Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer



Rating:

Share or cite this content

Citations should be made in the following way:
J. A. Torrecilla, S. Scrimini, J. Sauleda, F. de Borja García-Cosío, A. Noguera, A. Iglesias, A. Ríos, R. Córdova, A. Agustí (Palma Mallorca, Bunyola, Barcelona, Madrid, Spain). Role of C reactive protein in non small cell lung cancer staging. Eur Respir J 2011; 38: Suppl. 55, 2806

Member's Comments

No comment yet.

Related content which might interest you: Potential diagnostic markers in bronquial fluid of patients with non small cell lung cancer (NSCLC) Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009 The role of VATS in the staging of non small cell lung cancer Source: Annual Congress 2011 - General thoracic surgery I Year: 2011 Clinical significance of serum cathepsin K level during chemotherapy of lung cancer. Can we use it as a marker of small cell lung cancer? Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008 Does expression of betatubulin 3 correlate between primary non small cells lung cancer tumor and metastases? Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 Cyclooxygenase(COX)-2 is over-expressed in non small cell lung cancer (NSCLC) and is a potential target for treatment Source: Eur Respir J 2002; 20: Suppl. 38, 400s Year: 2002 Chemotherapy in advanced non small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 77s Year: 2005 Adenylate cyclase-associated protein 1 is associated with metastasis of non-small cell lung cancer especially in brain metastasis patients and promotes the lung cancer cell proliferation and migration in vitro as well as its growth and metastasis in vivo by the signaling pathways of limk1-cofilin Source: International Congress 2015 – New frontiers in biomedical research on thoracic tumours Year: 2015 Staging with FDG-PET/CT influences stage-specific survival in non small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Imaging in oncology and infectious diseases Year: 2011 Circulating free DNA, new dynamic marker in nonsmall cell lung cancer patients? Source: Eur Respir J 2015; 46: 1548-1550 Year: 2015 Are there potential characteristical markers in bronquial fluid for diagnosis of small cell lung cancer (SCLC)? Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009 In vitro and in vivo application of the GILUPI cell collector system for the isolation and characterization of circulating tumor cells (CTCs) in lung cancer patients Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer Year: 2015 Evaluation by immunohistochemistry of EGF-R expression before and after chemotherapy in non small cell lung cancer Source: Annual Congress 2005 - Chemotherapy and palliative care Year: 2005 Extrathoracic 18-FDG-PET uptakes in non small cell lung cancer (NSCLC) preoperative staging Source: Eur Respir J 2007; 30: Suppl. 51, 430s Year: 2007 Small cell lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Pattern of relapse in stage I N0 non small cell lung cancer Source: Annual Congress 2009 - Preoperative functional assessment and surgery for malignant diseases Year: 2009 Small cell lung cancer in patients with elderly Source: Annual Congress 2007 - Therapy of lung cancer Year: 2007 Telomerase activity as a prognostic marker in non small cell lung cancer Source: Annual Congress 2008 - Diagnosis and prognosis in thoracic oncology Year: 2008